{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:22:42Z","timestamp":1783700562291,"version":"3.55.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020400","name":"John Black Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031315","name":"AstraZeneca UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Clinical trials show benefit of the combination of poly(ADP-ribose) polymerase inhibitors (PARPi) with androgen receptor (AR) pathway inhibitors (ARPi) in metastatic, castration-resistant prostate cancer. While benefit was evident in patients with tumours harbouring mutations in homologous recombination repair (HRR) genes, improved outcomes were also observed in the absence of such alterations. Although there is literature linking AR with DNA repair, the basis of the interaction between the AR and PARP is unclear. We show that benefit of the combination of ARPi and PARPi in prostate cancer models with no HRR mutations requires ARPi-responsive cells and a PARPi with PARP1-trapping activity, and does not involve an effect of PARPi treatment in modulating AR transcription. Combination benefit is driven by an increase in DNA double-strand breaks and micronuclei formation, which is not due to a control of HRR gene transcription by the AR. Also, we uncover a novel role of PARP1 modulating AR recruitment to chromatin in the presence of DNA damage. These data shed light on the interplay between PARP1 and the AR in dealing with genotoxic insults and provide a mechanism-of-action consistent with the clinical benefit of the combination of PARPi and ARPi in patients with prostate cancer.<\/jats:p>","DOI":"10.1093\/narcan\/zcaf035","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T10:24:47Z","timestamp":1759832687000},"source":"Crossref","is-referenced-by-count":6,"title":["Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1358-8424","authenticated-orcid":false,"given":"Giuditta","family":"Illuzzi","sequence":"first","affiliation":[{"name":"Bioscience, Oncology R&D , AstraZeneca, 1 Francis Crick Avenue,\u00a0Cambridge CB2 0AA,\u00a0","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Galbiati","sequence":"additional","affiliation":[{"name":"Bioscience, Oncology R&D , AstraZeneca, 1 Francis Crick Avenue,\u00a0Cambridge CB2 0AA,\u00a0","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna\u00a0D","family":"Staniszewska","sequence":"additional","affiliation":[{"name":"Bioscience, Oncology R&D , AstraZeneca, 1 Francis Crick Avenue,\u00a0Cambridge CB2 0AA,\u00a0","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hanson","sequence":"additional","affiliation":[{"name":"Translational Medicine, Oncology R&D , AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA,\u00a0Cambridge,\u00a0","place":["UK"]},{"name":"Early Cancer Institute,\u00a0Cancer Research UK Cambridge Centre; Department of Oncology, University of Cambridge Hutchison-MRC Research Centre, Adrian Way,\u00a0 Cambridge CB2 0AH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysiis","family":"Michaloglou","sequence":"additional","affiliation":[{"name":"Bioscience, Oncology R&D , AstraZeneca, 1 Francis Crick Avenue,\u00a0Cambridge CB2 0AA,\u00a0","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie\u00a0L","family":"Cooke","sequence":"additional","affiliation":[{"name":"Bioscience, Oncology R&D , AstraZeneca, 1 Francis Crick Avenue,\u00a0Cambridge CB2 0AA,\u00a0","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Uzna\u0144ska","sequence":"additional","affiliation":[{"name":"intoDNA S.A. ,\u00a0Bobrzy\u0144skiego 14, 30-348 Krakow ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Bia\u0142ecka","sequence":"additional","affiliation":[{"name":"intoDNA S.A. ,\u00a0Bobrzy\u0144skiego 14, 30-348 Krakow ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Solarczyk","sequence":"additional","affiliation":[{"name":"intoDNA S.A. ,\u00a0Bobrzy\u0144skiego 14, 30-348 Krakow ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harveer\u00a0S","family":"Dev","sequence":"additional","affiliation":[{"name":"Early Cancer Institute,\u00a0Cancer Research UK Cambridge Centre; Department of Oncology, University of Cambridge Hutchison-MRC Research Centre, Adrian Way,\u00a0 Cambridge CB2 0AH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie\u00a0E","family":"Massie","sequence":"additional","affiliation":[{"name":"Early Cancer Institute,\u00a0Cancer Research UK Cambridge Centre; Department of Oncology, University of Cambridge Hutchison-MRC Research Centre, Adrian Way,\u00a0 Cambridge CB2 0AH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u00a0R","family":"Albertella","sequence":"additional","affiliation":[{"name":"Bioscience, Oncology R&D , AstraZeneca, 1 Francis Crick Avenue,\u00a0Cambridge CB2 0AA,\u00a0","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Leo","sequence":"additional","affiliation":[{"name":"Bioscience, Oncology R&D , AstraZeneca, 1 Francis Crick Avenue,\u00a0Cambridge CB2 0AA,\u00a0","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7797-2583","authenticated-orcid":false,"given":"Josep\u00a0V","family":"Forment","sequence":"additional","affiliation":[{"name":"Bioscience, Oncology R&D , AstraZeneca, 1 Francis Crick Avenue,\u00a0Cambridge CB2 0AA,\u00a0","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1823-625X","authenticated-orcid":false,"given":"Mark\u00a0J","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Bioscience, Oncology R&D , AstraZeneca, 1 Francis Crick Avenue,\u00a0Cambridge CB2 0AA,\u00a0","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"2025100706243910500_B1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3389\/fonc.2019.00801","article-title":"Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer","volume":"9","author":"Rice","year":"2019","journal-title":"Front Oncol"},{"key":"2025100706243910500_B2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","author":"Stewart","year":"2022","journal-title":"Oncologist"},{"key":"2025100706243910500_B3","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025100706243910500_B4","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"2025100706243910500_B5","doi-asserted-by":"publisher","first-page":"362ps317","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci Transl Med"},{"key":"2025100706243910500_B6","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2025100706243910500_B7","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de\u00a0Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"2025100706243910500_B8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100706243910500_B9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025100706243910500_B10","first-page":"EVIDoa2200043","article-title":"Abiraterone and Olaparib for metastatic castration-resistant prostate cancer","volume":"0","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"2025100706243910500_B11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"The Lancet"},{"key":"2025100706243910500_B12","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","article-title":"A hormone\u2013DNA repair circuit governs the response to genotoxic insult","volume":"3","author":"Goodwin","year":"2013","journal-title":"Cancer Discov"},{"key":"2025100706243910500_B13","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov"},{"key":"2025100706243910500_B14","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"key":"2025100706243910500_B15","doi-asserted-by":"publisher","first-page":"eaam7479","DOI":"10.1126\/scisignal.aam7479","article-title":"Androgen receptor inhibitor-induced BRCAness and PARP inhibition are synthetically lethal for castration-resistant prostate cancer","volume":"10","author":"Li","year":"2017","journal-title":"Sci Signal"},{"key":"2025100706243910500_B16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat Commun"},{"key":"2025100706243910500_B17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.21037\/tau.2018.01.06","article-title":"Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy","volume":"7","author":"Siddiqui","year":"2018","journal-title":"Transl Androl Urol"},{"key":"2025100706243910500_B18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminoncol.2023.09.003","article-title":"PARP inhibitors for prostate cancer","volume":"51","author":"Longoria","year":"2023","journal-title":"Semin Oncol"},{"key":"2025100706243910500_B19","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1158\/2767-9764.CRC-22-0119","article-title":"Drug\u2013gene interaction screens coupled to tumor data analyses identify the most clinically relevant cancer vulnerabilities driving sensitivity to PARP inhibition","volume":"2","author":"Jamal","year":"2022","journal-title":"Cancer Res Commun"},{"key":"2025100706243910500_B20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3892\/ijo.2015.3062","article-title":"Combining AZD8931, a novel EGFR\/HER2\/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models","volume":"47","author":"Crafter","year":"2015","journal-title":"Int J Oncol"},{"key":"2025100706243910500_B21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/BF01952257","article-title":"\u00dcber kombinationswirkungen","volume":"114","author":"Loewe","year":"1926","journal-title":"Archiv F Experiment Pathol u Pharmakol"},{"key":"2025100706243910500_B22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2025100706243910500_B23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"2025100706243910500_B24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2025100706243910500_B25","doi-asserted-by":"publisher","article-title":"Fast gene set enrichment analysis","author":"Korotkevich","DOI":"10.1101\/060012"},{"key":"2025100706243910500_B26","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025100706243910500_B27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s40425-018-0457-0","article-title":"PI3K\u03b1\/\u03b4 inhibition promotes anti-tumor immunity through direct enhancement of effector CD8(+) T-cell activity","volume":"6","author":"Carnevalli","year":"2018","journal-title":"J Immunotherap Cancer"},{"key":"2025100706243910500_B28","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1093\/nar\/gkz1118","article-title":"STRIDE\u2014A fluorescence method for direct, specific in situ detection of individual single- or double-strand DNA breaks in fixed cells","volume":"48","author":"Kordon","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"2025100706243910500_B29","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical characterization of AZD5305, A next-generation, highly selective PARP1 inhibitor and trapper","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100706243910500_B30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41467-018-07729-2","article-title":"ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks","volume":"10","author":"Balmus","year":"2019","journal-title":"Nat Commun"},{"key":"2025100706243910500_B31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-023-07009-0","article-title":"Genetic determinants of micronucleus formation in vivo","volume":"627","author":"Adams","year":"2024","journal-title":"Nature"},{"key":"2025100706243910500_B32","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann Oncol"},{"key":"2025100706243910500_B33","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol Cell"},{"key":"2025100706243910500_B34","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.1093\/nar\/gkz286","article-title":"A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities","volume":"47","author":"Kounatidou","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2025100706243910500_B35","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1158\/1541-7786.MCR-23-0358","article-title":"The androgen receptor does not directly regulate the transcription of DNA damage response genes","volume":"21","author":"Hasterok","year":"2023","journal-title":"Mol Cancer Res"},{"key":"2025100706243910500_B36","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1200\/JCO.2017.75.7310","article-title":"Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012","volume":"36","author":"Hussain","year":"2018","journal-title":"JCO"},{"key":"2025100706243910500_B37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.2024.42.4_suppl.19","article-title":"BRCAAway: a randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm)","volume":"42","author":"Hussain","year":"2024","journal-title":"JCO"},{"key":"2025100706243910500_B38","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and Abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"JCO"}],"container-title":["NAR Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/narcancer\/article-pdf\/7\/4\/zcaf035\/64528430\/zcaf035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/narcancer\/article-pdf\/7\/4\/zcaf035\/64528430\/zcaf035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T10:24:49Z","timestamp":1759832689000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/narcancer\/article\/doi\/10.1093\/narcan\/zcaf035\/8276625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/narcan\/zcaf035","relation":{},"ISSN":["2632-8674"],"issn-type":[{"value":"2632-8674","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,7]]},"article-number":"zcaf035"}}